Market News
Smart Trading. Simplified.
The $62.7 Billion Medical "Gold Rush"
A small San Francisco company holds the secret to a medical breakthrough The Economist called "A Boon to Humanity?"
Jim Cramer says it would be "The Biggest Drug Ever."
And our research proves that anyone who gets in now could profit 8990%
Click Here to Learn How >>>
5 Dividend Aristocrats To Buy and Hold Forever
Earning the moniker of a dividend aristocrat is no easy feat for a publicly traded company on the New York Stock Exchange: the company has to show up in the S&P 500 index, the company has to routinely pay out a dividend to its shareholders, and the company has to increase the total payout of […]
Jeff Bezos' Next Big Thing
The tech visionary who built a revolutionary $1.6 trillion company from scratch is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's.
Early investors who get in by October 6th, 2021, could turn every $1,000 into $1.1 million.
Will Bill.com Stock Go Up?
Accounting software has been around nearly as long as personal computers, but even the most accurate and user-friendly locally-hosted platforms have a problem. It’s the same problem that plagues all locally-hosted software: staying up-to-date. In addition to the up-front costs and the storage required, traditional offline accounting software requires regular manual updates to stay current […]
Buy Gold & Silver with Your IRA/401(k) Using this IRS Loophole
Rollover your 401K to a precious metals IRA and protect yourself & family from inflation. From the #1 gold IRA Company, This free gold & silver IRA guide will show you how you can roll over your IRA or 401(k) into precious metals. Tax free & penalty-free into an IRA holding using a loophole the IRS doesn't want you to know!
Will The Stock Market Fall?
The March 2020 market crash was a shock to the global economy. Anxiety around the emerging COVID-19 pandemic had investors worried, causing a mass selloff. From February 12th to March 23rd, the Dow Jones Industrial Average went down by 37 percent. On March 13, 2020, Federal Reserve Chair Jerome Powell remarked that “The scope and […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
The Bull Case For eBay
Online shopping brands have been some of the most successful businesses to have capitalized on the increasing digitization of the global economy over the last few decades. One of the best known of these is eBay Inc. (EBAY), the San Jose-based American e-commerce giant that has seen its share price nearly triple since the beginning of […]
New Study: Americans Leaving on Average $97,347 on the Table
There's a new type of "retirement calculator" that's changing the way thousands of Americans invest. Employees at some of the richest money management firms on the planet are using this calculator, including big Wall Street banks like Bank of America, US Bank, Wells Fargo, Wachovia, Morgan Stanley, and UBS. It has been featured on Fox News, CNBC and Fox Business.
4 Meme Stocks To Buy
Meme stocks were popularized when a flurry of retail investors eschewed traditional fundamentals to invest in a company that had the potential to “stick it” to the hedge funds. It started on Reddit’s WallStreetBets subreddit, a 10-million-strong community of self-proclaimed apes who banded together to take down the hedge funds. The trend ignited a trading […]
A Rare Opportunity to Turn $1,000 into $461,800
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment